Ketchum Steven B, Chief Scientific Officer at Amarin Corporation (NASDAQ: AMRN), has demonstrated a consistent pattern of stock sales over multiple years, with no recent purchases recorded in SEC filings. His transactions, totaling $207,104 in sales against $20,467 in buys across 32 trades, reflect a net disposition of shares. The majority of these sales occurred through derivative transactions coded as "F" (typically representing the sale of shares acquired via option exercises or other non-open-market means). Notable sales include a $28,492 disposition on January 2, 2026, and multiple transactions in late January 2025 and 2026, such as $19,044 and $16,376 sales on January 31, 2026.
Ketchum’s activity is concentrated solely in Amarin, with no trades in other companies. The absence of open-market purchases in recent filings suggests a lack of accumulation, though the zero-dollar "A"-coded transactions (likely representing grants or awards) indicate ongoing equity compensation. The sales, often clustered around year-end and early-year periods, follow a recurring pattern without drastic deviations in size or timing. While the dollar amounts are modest compared to executive trades at larger firms, the consistency of dispositions over acquisitions may signal a gradual reduction in exposure rather than an abrupt shift in position.
AI-assisted summary